Introduction: Hidradenitis suppurativa is a persistent, inflammatory and recurrent disease of the hair follicles which, in time, results in ugly scars. Inflammation and obstruction of channel of sweat glands used to be thought to be the basis of this disease.
Case Reports: This paper presents the cases of 8 patients operated on in the past 3 years. A possibility of an oversight in making the diagnosis, as well as an underestimation in the treatment should be taken into consideration. In addition to surgical methods the authors discuss other therapeutic possibilities taken from the available literature. This is a retrospective analysis of the surgical findings. The treatment was multidisciplinary but the surgical excision was the only option which provided healing without recurrence so far. In our series the excision could be done to the fascia or to leave a thin layer of adipose tissue. The reconstruction could be achieved by healing per secundam, by autologous skin or artificial graft, or by narrowing the wound with a skin portion. Our results achieved by stage, secondary stitches and rotation portions were satisfying.
Conclusion: In case of advanced disease only surgery can lead to healing. We performed late surgery because the disease was diagnozed in advanced stages according to Hurlay. Wide excision was done in all our patients. The reconstruction was achieved with rotational flap in 3 patients, the wound healing per secundam in 4 patients and with primary suture in one patient. Our patients did not have recurrences of the primary disease. The disease was combined in one case with perianal fistula.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2298/mpns1602048s | DOI Listing |
Plast Reconstr Surg Glob Open
January 2025
Division of Plastic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that often necessitates extensive surgery when medical treatment fails, particularly in advanced stages. Traditional surgical approaches, including flaps and skin grafts, are effective for tissue coverage but can lead to vascular complications and recurrence of HS. This study introduces a novel technique, the apple-peeling procedure, combined with negative pressure wound therapy at -50 mm Hg for 5 days postoperatively.
View Article and Find Full Text PDFClin Cosmet Investig Dermatol
January 2025
College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Background: Hidradenitis suppurativa (HS) is a complex condition that is often misdiagnosed, and regional data on its clinical features and risk factors are limited. This study aimed to explore the clinical epidemiology and phenotypic characteristics of HS in the central region of Saudi Arabia.
Materials And Methods: A cross-sectional study was conducted on HS patients at King Khalid University Hospital (KKUH) in Riyadh from December 2020 to December 2021.
J Community Hosp Intern Med Perspect
November 2024
Medstar Health Internal Medicine Residency Program, Baltimore, MD, USA.
The co-occurrence of inflammatory eye disease and hidradenitis suppurativa (HS) is uncommon; ocular involvement typically manifests as anterior uveitis. In this report, we present a unique case of peripheral ulcerative keratitis (PUK) where both infectious and rheumatological workup was negative, leading us to consider the possibility of an association between this condition and severe HS. As far as we are aware, there have only been six documented cases of PUK associated with HS.
View Article and Find Full Text PDFClin Exp Dermatol
January 2025
Department of Dermatology, University of Virginia, Charlottesville, Virginia, USA.
Hidradenitis suppurativa (HS) patients treated with tumor necrosis factor (TNF) inhibitors are at an increased risk for tuberculosis (TB) reactivation, necessitating baseline latent TB infection (LTBI) screening. However, evidence regarding the value of periodic LTBI screening in this population is limited. In this single-center retrospective chart review, we investigated the LTBI rate in HS patients treated with adalimumab or infliximab.
View Article and Find Full Text PDFJAAD Case Rep
January 2025
Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!